Calendario›MIST›Etripamil NS
Etripamil NS
Ensayo de Milestone Pharmaceuticals Inc. en Taquicardia supraventricular paroxística.
Todo sobre el fármaco: Etripamil NS.
- Fase
- Fase 2
- Estado
- Reclutando pacientes
- Participantes
- 60
- Centros
- 10
- Fin del objetivo primario
- jun 2027
Título oficial en el registro (en inglés): The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
Qué significa cada fase y cada estado.
Estudio de intervención, de un solo grupo, abierto. Comenzó en dic 2023.
De principio a fin
- Empieza el ensayo (dic 2023)
- Hoy
- Lectura de resultados jun 2027 (prevista)
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
Eficacia: porcentaje de pacientes que recuperan el ritmo sinusal (RS) en los primeros 15 minutos tras la administración de etripamil NS. (15 minutes after administration of etripamil NS) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroNODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a symptomatic episode of PSVT. In Part 1, at least 30 patients aged 12 to \<18 years will be enrolled and treated with etripamil nasal spray (NS). Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of 70 mg etripamil NS (Part 1A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the Pharmacokinetic (PK) analysis and will undergo efficacy and safety/tolerability assessments (Part 1B). In Part 2, at least 30 patients aged 6 to \<12 years will be enrolled and treated with etripamil NS at a dose selected based on appropriate body size-based modeling, as well as efficacy, safety/tolerability, and PK data collected in Part 1. Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of etripamil NS (Part 2A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the PK analysis and will undergo efficacy and safety/tolerability assessments (Part 2B). The study will include the following visits: A Screening Visit, A Treatment Visit, , and A Follow-Up/End of Study Visit.
Más ensayos de MIST
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Etripamil · ReVeRA-301 | Fase 3 | Reclutando pacientes | dic 2028 (prevista) |
| Etripamil NS 70 mg | Fase 3 | Completado | abr 2026 (real) |
| Etripamil | Fase 2 | Completado | ago 2023 (real) |
| Etripamil NS | Fase 3 | Completado | ene 2023 (real) |
| Etripamil · NODE-301 | Fase 3 | Interrumpido | ene 2023 (real) |
| Etripamil NS 70 mg | Fase 3 | Interrumpido | nov 2020 (real) |
Todos los de MIST, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05763953), actualizada en jul 2026.